🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The human and economic impact of chronic respiratory diseases like asthma and COPD continues to grow. Leading experts outline why earlier, more proactive intervention is needed to improve outcomes for patients, society, and the planet. Learn more: learn.az/6011WC7eU.

We’re following the science to better understand the complex pathways behind immune-driven diseases, such as cutaneous lupus erythematosus (CLE). Through more targeted and proactive approaches, we aim to transform outcomes for patients. Learn more: learn.az/6014oPThQ

🌟 Big news! We've been honoured with the Corporate Social Responsibility Programme of the Year at the Pharma Industry UK Awards 2024 and a Bronze for Best Community Involvement at the Corporate Engagement Awards 2024. Proud moment for our team! #YoungHealthProgramme

As part of our commitment to sustainable science and innovation, we’re accelerating progress towards net zero by decarbonising our clinical trials. 🌍 Learn more: learn.az/6018WHoPA #WhatScienceCanDo

Digital biomarkers can help scientists better understand #RareDiseases and develop medicines to address unmet treatment needs. Learn more about this powerful research tool: learn.az/6018UOJma #WhatScienceCanDo

We’re driving sustainable science, ensuring that our clinical trials represent the diversity of the communities we serve. Discover more: learn.az/6010SJWmm #WhatScienceCanDo

The landscape of lupus care is changing rapidly, yet challenges to care persist. Profs. Ian Bruce and Julia Weinmann-Menke discuss how the current state of lupus care can be transformed to make achieving lasting remission a priority learn.az/6013Sp5T3

Our #YoungHealthProgramme Impact Fellows attended One Young World, and developed their global network of young leaders. Learn more here: learn.az/6017ST3R5 #OYW24

We’re supporting the launch of a new Patient Charter, calling for improvements in the quality of care for those living with systemic lupus erythematous. Learn more on how the lupus community is uniting to drive change: learn.az/6019S4p5z

Congratulations to Pam Cheng, our EVP of Global Operations & IT and Chief Sustainability Officer, who has been named by #TIME100Climate as one of the top global leaders driving climate action. learn.az/6016sMh8m

COPD is responsible for 425 deaths every hour. You can help change this statistic. Early detection and diagnosis paired with timely access to comprehensive care can reduce the burden. This #WorldCOPDDay, take a stand against COPD: learn.az/6016s6eBC #SpeakUpforCOPD

From lab to patient, we’re focused on sustainable science and leveraging digital advances such as electronic product information (ePI), unlocking benefits for people, society and the planet. Learn more: learn.az/6010Q1ZU0

We’re setting new standards in sustainable science, becoming the first organisation to achieve the new My Green Lab 2.0 Certification. We have over 78 lab spaces certified and 65 achieved the highest certification level – Green. #WhatScienceCanDo #GreenLabs #RacetoZero

2024 was another year of double-digit growth with continued scientific progress across all Therapy Areas. Our total annual dividend increased by 7% to $3.10 per share and will further increase in 2025. Watch CEO Pascal Soriot share our Full Year and Q4 2024 results. #AZN

Are you a young leader advocating for greater health equity? Now’s the time to apply to the Young Health Programme Impact Fellowship in partnership with One Young World: learn.az/6011LU8TU #YoungHealthProgramme #OYW25

🌍 Calling all youth leaders in global health equity! Join our Young Health Programme Impact Fellowship for a fully funded One Young World scholarship, financial grant, and development opportunities. Apply now: learn.az/6018FZLFp #OYW25 #YoungHealthProgramme

#News for #Investors and #Media📈 We continued our strong growth momentum into 2025 with Total Revenue increasing by 10%, driven by double-digit growth across Oncology/ Haematology and BioPharmaceuticals. #AZN #FinancialResults